Speaker illustration

Doctor Tomoaki Okada

Kagawa Prefectural Central Hospital, Takamatsu (Japan)

Member of:

Heart Failure Association

Feasibility and safety of early initiation of a PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor in patients with acute myocardial infarction undergoing primary PCI

Event: ESC Congress 2020

Topic: Lipid-Lowering Agents

Session: Pharmacology and Pharmacotherapy ePosters


ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb